Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum has reiterated a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a price target of $17.
July 21, 2023 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a 'Buy' rating on Recursion Pharmaceuticals, maintaining a price target of $17.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $17 price target indicates a positive outlook for Recursion Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100